You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Androgen receptor targeted agent

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic Trial in Leuven (Radiotherapy (SBRT) and/or surgery

Recruiting
  • Prostate Cancer
  • +6 more
  • Radiotherapy (SBRT) and/or surgery (metastasectomy)
  • +2 more
  • Leuven, Belgium
    University Hospitals Leuven
Jun 7, 2022

Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer Trial in

Recruiting
  • Castration-Resistant Prostatic Cancer
  • +4 more
  • Orange City, Florida
  • +1 more
Nov 23, 2022

Prostate Cancer Trial in Boston, Brooklyn, New York (225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Sep 20, 2021

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer Trial in United States (VERU-111,

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Androgen Resistant Prostatic Cancer
  • Anchorage, Alaska
  • +43 more
Jan 3, 2023

Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +7 more
  • Biopsy
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

Not yet recruiting
  • PIK3CA Mutation
  • +7 more
  • (no location specified)
Mar 7, 2023

Breast Tumors Trial in Nagoya, Kashiwa, Chuo-ku (ARV-471)

Not yet recruiting
  • Breast Neoplasms
  • Nagoya, Aichi, Japan
  • +2 more
Aug 12, 2022

Breast Cancer With or Without BRCA Mutation

Recruiting
  • Breast Cancer
  • Androgen receptor status and BRCA mutation
  • Varanasi, UP, India
    Banaras Hindu University
Jun 2, 2022

Prostate Cancer Trial in Baltimore (18F-DCFPyL Injection)

Withdrawn
  • Prostate Cancer
  • 18F-DCFPyL Injection
  • Baltimore, Maryland
    Johns Hopkins University
Dec 14, 2021

Prostate Cancer Metastatic Trial in France (Darolutamide 300 mg, Placebo, Androgen deprivation therapy)

Recruiting
  • Prostate Cancer Metastatic
  • Darolutamide 300 mg
  • +2 more
  • Avignon, France
  • +44 more
Sep 28, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory

Active, not recruiting
Has Results
  • Castration Levels of Testosterone
  • +9 more
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
  • +2 more
Apr 4, 2022

Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Trial in San Francisco, Baltimore, Boston

Active, not recruiting
  • Castration-resistant Prostate Cancer
  • +2 more
  • San Francisco, California
  • +2 more
Nov 16, 2021

Solid Tumors, Advanced Cancer Trial in Houston (Anastrozole, Bevacizumab, Everolimus)

Completed
  • Solid Tumors
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2021

Prostatic Tumors Trial in Canada, United States (Niraparib, Apalutamide, Abiraterone Acetate)

Completed
  • Prostatic Neoplasms
  • West Hollywood, California
  • +5 more
Jul 16, 2020

Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Seviteronel-D (Seivteronel in combination with dexamethasone)
  • Docetaxel
  • (no location specified)
Sep 21, 2021

Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Acapatamab, Enzalutamide, Abiraterone)

Active, not recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Birmingham, Alabama
  • +13 more
Jun 20, 2022

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

PET/CT Characterization of Treatment Resistance

Recruiting
  • Prostate Cancer
  • F-fluorodeoxyglucose positron emission tomography (FDG PET)
  • prostate-specific membrane antigen positron emission tomography (PSMA PET)
  • Madison, Wisconsin
    University of Wisconsin
Jan 24, 2023

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Cancer Of Prostate Trial run by the National Cancer Institute (NCI) (M9241, Stereotactic Body Radiation Therapy (SBRT))

Recruiting
  • Cancer Of Prostate
  • M9241
  • Stereotactic Body Radiation Therapy (SBRT)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal

Unknown status
  • Metastatic Breast Cancer
  • Hormonal therapy-based treatments
  • Taipei, Taiwan
  • +1 more
Jan 11, 2021

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Metastatic Breast Cancer Trial in Worldwide (Enobosarm, Exemestane)

Recruiting
  • Metastatic Breast Cancer
  • Anchorage, Alaska
  • +58 more
Jan 6, 2023

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Prostate Cancer Trial in United States (ARN-509, LHRH Agonist)

Completed
Has Results
  • Prostate Cancer
  • Scottsdale, Arizona
  • +4 more
Feb 27, 2020